---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-082342"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2023-07-19T23:59:59+00:00"
generated_at: "2026-06-13T06:14:26.662032+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# BrainStorm Cell Therapeutics announces $7.5M registered direct offering of common stock and warrants

## Summary
- 4,054,055 shares at $1.85 each, each with a warrant to purchase one share at $2.00 for five years.
- Gross proceeds of ~$7.5M before placement agent fees and expenses.
- Closing expected July 19, 2023; Maxim Group LLC is sole placement agent.
- Offered under existing S-3 shelf registration statement (File No. 333-258640).

## SEC filing metadata
- accession: 0001104659-23-082342
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2023-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465923082342/0001104659-23-082342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465923082342/tm2321519d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-082342
- JSON: https://secwatch.observer/filing/0001104659-23-082342.json
- Plain text: https://secwatch.observer/filing/0001104659-23-082342.txt

## Key facts
- Material Agreements
  BRAINSTORM CELL THERAPEUTICS INC. entered into Purchase Agreement valued at approximately $7.5 million (effective 2023-07-17).
  - Action: entry
  - Agreement: equity purchase
  - Value: approximately $7.5 million
  - Effective: 2023-07-17
  source text: On July 17, 2023, Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to sell, in a public offering (the “Offering”), an aggregate of 4,054,055 shares of the Company’s common stock, par value $0.00005 per share (the “Common Stock”), together with accompanying warrants (the “Common Warrants”) to purchase 4,054,055 shares of Common Stock, at a purchase price of $1.85 per share and accompanying warrants for gross proceeds to the Company of approximately $7.5 million, before deducting fees payable to the placement agent and other estimated offering expenses payable by the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923082342/0001104659-23-082342-index.htm
- Material Agreements
  BRAINSTORM CELL THERAPEUTICS INC. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-07-17).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Maxim Group LLC
  - Effective: 2023-07-17
  source text: the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim”) , pursuant to which Maxim agreed to serve as exclusive placement agent for the issuance and sale of the shares of Common Stock and accompanying Common Warrants.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923082342/0001104659-23-082342-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.